Literature DB >> 3377568

Splenectomy in hematologic disorders. The ever-changing indications.

M C Wilhelm1, R E Jones, R McGehee, J S Mitchener, W R Sandusky, C E Hess.   

Abstract

A comparison between a series of splenectomies performed at the University of Virginia Medical Center for hematologic disorders between 1946 and 1962 (Series I) and 1963 and 1982 (Series II) is presented. Four hundred splenectomies (20 per year) were performed between 1963 and 1982 compared with 94 (5.5 per year) between 1946 and 1962. Also noted in Series II was a sharp decline in the number performed each year between 1974 and 1983. The major factor responsible for these observations was the evolution of the staging laparotomy for malignant lymphomas, particularly Hodgkin's disease, and the decline in the average annual incidence of staging laparotomies since 1974. Staging laparotomy currently is rarely done for non-Hodgkin's lymphomas. Also contributing to the changes noted was an increase in the total number but subsequent fall in the annual incidence of splenectomy for hereditary spherocytosis, idiopathic hypersplenism, and myeloproliferative disorders in Series II. The average number of splenectomies for idiopathic thrombocytopenic purpura increased from 1.1 per year in Series I to 3.6 per year in Series II; the annual incidence during the study period of Series II, however, remained constant. The total number of splenectomies for hairy cell leukemia and Felty's syndrome increased from zero in Series I to 12 and 17, respectively, in Series II, whereas the number of miscellaneous reasons dropped from 29 (1.7 per year) in Series I to 15 (0.75 per year) in Series II. The mortality rate in Series I was 6.3% compared with 4.0% in Series II. No deaths occurred in Series II after 1979. Indications for splenectomy in Series II were for diagnostic purposes in 3.2%, therapeutic in 56.5%, staging in 39.5%, and restaging in 0.8%. Accessory spleens were found in 49 (12.5%) in Series II.

Entities:  

Mesh:

Year:  1988        PMID: 3377568      PMCID: PMC1493478          DOI: 10.1097/00000658-198805000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

Review 1.  Hematologic indications for splenectomy.

Authors:  H L Dameshek; L D Ellis
Journal:  Surg Clin North Am       Date:  1975-04       Impact factor: 2.741

2.  SPLENECTOMY: INDICATIONS AND RESULTS IN HEMATOLOGIC DISORDERS.

Authors:  W R SANDUSKY; B S LEAVELL; B I BENJAMIN
Journal:  Ann Surg       Date:  1964-05       Impact factor: 12.969

3.  Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma.

Authors:  B A Chabner; R E Johnson; R C Young; G P Canellos; S P Hubbard; S K Johnson; V T DeVita
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

4.  Mechanism of dilutional anemia in massive splenomegaly.

Authors:  C E Hess; C R Ayers; W R Sandusky; M A Carpenter; R A Wetzel; D N Mohler
Journal:  Blood       Date:  1976-04       Impact factor: 22.113

5.  Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas.

Authors:  D R Goffinet; R Warnke; N R Dunnick; R Castellino; E Glatstein; T S Nelsen; R F Dorfman; S A Rosenberg; H S Kaplan
Journal:  Cancer Treat Rep       Date:  1977-09

6.  Idiopathic thrombocytopenic purpura. Long-term results of treatment and the prognostic significance of response to corticosteroids.

Authors:  R L Thompson; R A Moore; C E Hess; M S Wheby; B S Leavell
Journal:  Arch Intern Med       Date:  1972-11

7.  Felty's syndrome: long-term follow-up after splenectomy.

Authors:  R A Moore; C M Brunner; W R Sandusky; B S Leavell
Journal:  Ann Intern Med       Date:  1971-09       Impact factor: 25.391

8.  Staging laparotomy in Hodgkin's disease.

Authors:  W R Sandusky; R C Jones; J S Horsley; W L Marsh; T W Tillack; C J Tegtmeyer; C E Hess
Journal:  Ann Surg       Date:  1978-05       Impact factor: 12.969

9.  The value of laparotomy and splenectomy in the staging of Hodgkin's disease.

Authors:  E Glatstein; J M Guernsey; S A Rosenberg; H S Kaplan
Journal:  Cancer       Date:  1969-10       Impact factor: 6.860

10.  Splenectomy in the management of haematological disease.

Authors:  A A Dawson; P F Jones; D J King
Journal:  Br J Surg       Date:  1987-05       Impact factor: 6.939

View more
  7 in total

1.  Hand-assisted laparoscopic splenectomy versus open splenectomy for massive splenomegaly: 20-year experience at a Canadian centre.

Authors:  Todd W Swanson; Adam T Meneghetti; Sharadh Sampath; Joseph M Connors; O Neely M Panton
Journal:  Can J Surg       Date:  2011-06       Impact factor: 2.089

Review 2.  HIV-1-associated thrombocytopenia. The role of splenectomy.

Authors:  D S Tyler; S Shaunak; J A Bartlett; J D Iglehart
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

3.  Splenectomy in patients with undiagnosed splenomegaly.

Authors:  C C Cronin; M P Brady; C Murphy; E Kenny; M J Whelton; C Hardiman
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

4.  Laparoscopic splenectomy in patients with hematologic diseases.

Authors:  J L Flowers; A T Lefor; J Steers; M Heyman; S M Graham; A L Imbembo
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

5.  Postoperative complications after splenectomy for hematologic malignancies.

Authors:  J Horowitz; J L Smith; T K Weber; M A Rodriguez-Bigas; N J Petrelli
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

6.  Splenectomy in a general hospital.

Authors:  J M Glass; J M Gilbert
Journal:  J R Soc Med       Date:  1996-04       Impact factor: 18.000

7.  Recommendations regarding splenectomy in hereditary hemolytic anemias.

Authors:  Achille Iolascon; Immacolata Andolfo; Wilma Barcellini; Francesco Corcione; Loïc Garçon; Lucia De Franceschi; Claudio Pignata; Giovanna Graziadei; Dagmar Pospisilova; David C Rees; Mariane de Montalembert; Stefano Rivella; Antonella Gambale; Roberta Russo; Leticia Ribeiro; Jules Vives-Corrons; Patricia Aguilar Martinez; Antonis Kattamis; Beatrice Gulbis; Maria Domenica Cappellini; Irene Roberts; Hannah Tamary
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.